Effect of paclitaxel in combination with the beta2 adrenergic agonist salbutamol on breast cancer MDA-MB-231 cell line growing in vivo. Mechanism of action.

RIVERO E; APARICIO E; LÜTHY IA; JABLOÑSKI M; BRUQUE CD; PÉREZ PIÑERO C; RODRÍGUEZ MS; BRUZZONE A

Buenos Aires

Congreso; Reunión Biociencias 2020; 2020

SAIC, SAI, SAFIS

Breast cancer is the leading cancer death cause of women in Argentina. Beta2 adrenergic receptors have been described in several breast cancer cell lines and tumors. We have previously described(SAIC 2016, abstract 723) that the beta2 adrenergic agonist salbutamol exerted in vitro a synergic effect with paclitaxel inhibiting cell proliferation. The aim of the present study was to assess thein vivo effect of the combination of paclitaxel and salbutamol in the triple-negative MDA-MB-231 cell line growing in nude mice. Both salbutamol (daily sc 1.2 mg/kg/day) and paclitaxel (10 mg/kg/week, ip in two injections) significantly inhibited tumor growth. Moreover, their combination inhibited very significantly this parameter. For example, day 63 (mean ± SEM in mm2): control tumors: 46,5 ± 9,70, n=8; paclitaxel: 32.4 ± 6,40, n=7, p